{"id":9771,"date":"2026-03-24T17:43:59","date_gmt":"2026-03-24T14:43:59","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9771"},"modified":"2026-03-24T17:43:59","modified_gmt":"2026-03-24T14:43:59","slug":"when-to-use-lpa-cac-in-1-prevention-when-risk-is-unclear-gray-zone-2","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/when-to-use-lpa-cac-in-1-prevention-when-risk-is-unclear-gray-zone-2\/","title":{"rendered":"When to Use Lp(a) & CAC in 1\u00b0 Prevention: When Risk Is Unclear (Gray Zone)"},"content":{"rendered":"
When to Use Lp(a) & CAC in 1\u00b0 Prevention: When Risk Is Unclear (Gray Zone)<\/div>\n
<\/div>\n
Source: TCTMD<\/div>\n
Date: March 19, 2026<\/div>\n
Link: https:\/\/www.tctmd.com\/news\/lpa-and-cac-levels-independently-predict-long-term-ascvd-risk<\/div>\n
<\/div>\n
When to Use CAC<\/div>\n
\u2022 Primary prevention<\/span><\/div>\n
\u2022 Intermediate or uncertain risk (gray zone)<\/span><\/div>\n
\u2022 Elevated Lp(a) with unclear treatment decision<\/span><\/div>\n
<\/div>\n
Key Findings (JACC, 2026)<\/div>\n
\u2022 Lp(a) and CAC independently predict 15-year ASCVD risk<\/span><\/div>\n
\u2022 Highest risk:<\/span><\/div>\n
\u2022 Lp(a) >50 mg\/dL + CAC >0 \u2192 HR ~3.0<\/span><\/div>\n
<\/div>\n
Important Insight<\/div>\n
\u2022 CAC = 0 \u2192 low absolute risk, even with high Lp(a); risk is slightly higher than with low Lp(a), but remains overall low.<\/span><\/div>\n
<\/div>\n
Risk Interpretation<\/div>\n
\u2022 Lp(a) done once in lifetime \u2192 genetic predisposition<\/span><\/div>\n
\u2022 CAC \u2192 actual atherosclerotic burden<\/span><\/div>\n
\u2192 Complementary tools<\/div>\n
<\/div>\n
Clinical Approach<\/div>\n
(in Gray Zone)<\/div>\n
\u2022 Start with baseline risk clinically or :<\/span><\/div>\n
\u2022 Use 10-year risk (PREVENT \/ PCE)<\/span><\/div>\n
\u2022 Classify: low \/ intermediate \/ high<\/span><\/div>\n
<\/div>\n
\u2022 Check risk enhancers( Comorbidities):<\/span><\/div>\n
\u2022 Elevated Lp(a)<\/span><\/div>\n
\u2022 chronic inflammation ; hs-CRP \u22652 mg\/L<\/span><\/div>\n
\u2022 CKD (eGFR <60)<\/span><\/div>\n
\u2022 Family history of premature ASCVD<\/span><\/div>\n
\u2022 Metabolic syndrome<\/span><\/div>\n
<\/div>\n
\u2022 If \u22651 enhancer AND decision remains unclear:<\/span><\/div>\n
\ud83d\udc49 Proceed to CAC<\/div>\n
<\/div>\n
CAC-Guided Decision<\/div>\n
\u2022 CAC = 0 \u2192 low short-term risk<\/span><\/div>\n
\u2192 consider deferring statin (selected patients)<\/div>\n
\u2022 CAC >0 \u2192 subclinical atherosclerosis<\/span><\/div>\n
\u2192 initiate statin<\/div>\n
\u2022 CAC \u2265100 \u2192 high risk<\/span><\/div>\n
\u2192 start primary prevention or intensify therapy<\/div>\n
<\/div>\n
Guideline Context<\/div>\n
\u2022 Lp(a) measurement:<\/span><\/div>\n
\u2022 Class I recommendation (once in a lifetime)<\/span><\/div>\n
<\/div>\n
Bottom Line<\/div>\n
\u2022 CAC clarifies risk in the gray zone<\/span><\/div>\n
\u2022 Focus on absolute risk and plaque burden<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

When to Use Lp(a) & CAC in 1\u00b0 Prevention: When Risk Is Unclear (Gray Zone) Source: TCTMD Date: March 19, 2026 Link: https:\/\/www.tctmd.com\/news\/lpa-and-cac-levels-independently-predict-long-term-ascvd-risk When to Use CAC \u2022 Primary prevention \u2022 Intermediate or uncertain risk (gray zone) \u2022 Elevated Lp(a) with unclear treatment decision Key Findings (JACC, 2026) \u2022 Lp(a) and CAC independently predict 15-year […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9771","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9771"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9771\/revisions"}],"predecessor-version":[{"id":9772,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9771\/revisions\/9772"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}